News

The $30m funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and Israeli biotechnology investors,

Advaxis’ proprietary technology generates innate immune stimulation, alongside potent and sustained T-cell responses. When combined with Sellas’ WT1 antigens, this has the potential to precisely direct an immune

In the phase 3 trial dubbed ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) in 344 catecholamine resistant hypotension patients, LJPC-501 demonstrated positive top-line results. The percentage

The companies will establish a joint venture (JV) and each share equally in the initial investment. Subject to necessary regulatory approvals, the construction on the initial phase of the facility

If approved, Tafinlar + Mekinist will be the first targeted treatment available for patients with BRAF V600-positive NSCLC. Of the estimated 1.8 million new cases of lung cancer

A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology

An approval from EMA would make the drug available for the treatment of hyperkalaemia in all the 28 member states of the European Union along with Iceland, Liechtenstein

V212 is the firm’s investigational inactivated VZV vaccine to prevent herpes zoster (HZ) and HZ-related complications in immunocompromised subjects with the age of 18 years and above. The

Sapacitabine (CYC682), an orally-available nucleoside analogue, acts via a novel DNA single-strand breaking mechanism, resulting in production of DNA double strand breaks (DSBs) and/or checkpoint activation. Primary endpoint of